. 2021 Oct 8;139(11):1684–1693. doi: 10.1182/blood.2020010263

Table 2.

Logistic models for POD24

	Induction treatment regimen
	All patients			Rituximab-chemotherapy			Rituximab			Chemotherapy
	Events/ total, n	OR (95% CI)	P	Events/ total, n	OR (95% CI)	P	Events/ total, n	OR (95% CI)	P	Events/ total, n	OR (95% CI)	P
Tier 1	1423/4751			459/2222			121/265			843/2264
Sex			<.0001^*			.0027^*			.6005^*			.0054^*
Female	655/2346	Reference	—	206/1106	Reference	—	63/140	Reference	—	386/1100	Reference	—
Male	768/2405	1.30 (1.14-1.47)	<.0001^†	253/1116	1.38 (1.12-1.70)	.0027^†	58/125	1.14 (0.69-1.88)	.6005^†	457/1164	1.28 (1.08-1.53)	.0054^†
Performance status			0.0001^*			0.0119^*			0.6770^*			0.0144^*
0-1	1301/4477	Reference	—	422/2111	Reference	—	117/258	Reference	—	762/2108	Reference	—
≥2	122/274	1.63 (1.27-2.10)	0.0001^†	37/111	1.71 (1.13-2.59)	0.0119^†	4/7	1.39 (0.29-6.56)	0.6770^†	81/156	1.52 (1.09-2.12)	0.0144^†
FLIPI risk category			<.0001^*			<.0001^*			0.0172^*			<.0001^*
Low	146/834	Reference	—	48/377	Reference	—	11/39	Reference	—	87/418	Reference	—
Intermediate	447/1772	1.58 (1.28-1.94)	<.0001^†	129/828	1.25 (0.87-1.79)	.2206^†	33/80	1.86 (0.80-4.29)	.1470^†	285/864	1.85 (1.40-2.44)	<.0001^†
High	830/2145	2.94 (2.41-3.59)	<.0001^†	282/1017	2.62 (1.87-3.66)	<.0001^†	77/146	2.90 (1.34-6.32)	.0072^†	471/982	3.45 (2.63-4.52)	<.0001^†
Tier 2	856/3046			389/1852			104/233			363/961
Sex			.0061^*			.0690^*			.4929^*			.0238^*
Female	410/1545	Reference	—	183/931	Reference	—	55/126	Reference	—	172/488	Reference	—
Male	446/1501	1.26 (1.07-1.48)	.0061^†	206/921	1.24 (0.98-1.56)	.0690^†	49/107	1.21 (0.71-2.06)	.4929^†	191/473	1.37 (1.04-1.81)	.0238^†
Performance status			.0268^*			.1743^*			.6284^*			.1072^*
0-1	789/2883	Reference	—	360/1762	Reference	—	102/228	Reference	—	327/893	Reference	—
≥2	67/163	1.46 (1.04-2.03)	.0268^†	29/90	1.39 (0.87-2.22)	.1743^†	2/5	0.63 (0.09-4.19)	.6284^†	36/68	1.53 (0.91-2.55)	.1072^†
FLIPI risk category			<.0001^*			<.0001^*			.0175^*			<.0001^*
Low	73/511	Reference	—	45/334	Reference	—	8/34	Reference	—	20/143	Reference	—
Intermediate	256/1123	1.69 (1.27-2.25)	.0003^†	104/674	1.08 (0.74-1.58)	.6803^†	27/68	2.22 (0.87-5.67)	.0963^†	125/381	2.87 (1.70-4.83)	<.0001^†
High	527/1412	3.14 (2.37-4.15)	<.0001^†	240/844	2.01 (1.39-2.90)	.0002^†	69/131	3.43 (1.42-8.24)	.0060^†	218/437	5.74 (3.40-9.67)	<.0001^†
Β2Μ level at baseline			<.0001^*			<.0001^*			.1509^*			.3200^*
Normal	504/2108	Reference	—	209/1278	Reference	—	75/182	Reference	—	220/648	Reference	—
Elevated	352/938	1.43 (1.19-1.70)	<.0001^†	180/574	1.81 (1.41-2.32)	<.0001^†	29/51	1.63 (0.84-3.16)	.1509^†	143/313	1.16 (0.86-1.56)	.3200^†

Type 3 Wald P-value.

^†

Covariate Wald P-value.